Neurizon’s NUZ-001 cleared by US FDA to enter the HEALEY ALS Platform trial Clearance marks official entry of NUZ-001 as Regimen “I” in the trial and follows a 30-day FDA review Milestone strengthens ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results